SLNO ALERT: Act Now on Securities Fraud Class Action!

Company Overview & Class Action Context

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is a small biopharmaceutical company focused on rare diseases, best known for developing VYKAT™ XR (diazoxide choline extended-release tablets) to treat hyperphagia in Prader-Willi syndrome (PWS) (www.globenewswire.com). After receiving FDA approval on March 26, 2025 for VYKAT XR – the first and only approved therapy for PWS hyperphagia – Soleno launched the drug in the U.S., driving its first-ever revenues and a swing to profitability by late 2025 (www.globenewswire.com) (www.globenewswire.com). However, the company’s post-launch trajectory was upended by serious controversy. In August 2025, activist short-seller Scorpion Capital published a scathing 415-page report alleging grave safety issues and fraud surrounding VYKAT XR (www.businesswire.com). Specifically, Scorpion reported a “rapid pile-up of children hospitalized for potential heart failure” after starting VYKAT XR, suggesting the drug might be so unsafe it could be withdrawn from the market (www.businesswire.com). Scorpion also accused Soleno of sham clinical trials and suspect data, claiming the company’s launch metrics “are hocus-pocus” – propped up by one “controversial physician” who led key trials and fueled initial patient starts (www.globenewswire.com). On the heels of these revelations, Soleno’s stock plunged ~8% on August 15, 2025 (www.businesswire.com) (and nearly 12–19% over the following two trading days, by some accounts (www.rgrdlaw.com) (www.rgrdlaw.com)). Worse, on September 10, 2025, Soleno disclosed an actual patient death linked to VYKAT XR (reported in the FDA’s adverse event database), triggering another 12% one-day drop (www.businesswire.com) (www.businesswire.com). These events set the stage for today’s securities fraud class action against Soleno and its top executives. Filed in November 2025 (City of Pontiac Police & Fire Ret. Sys. v. Soleno Therapeutics), the suit alleges that throughout March–Nov 2025 Soleno misled investors about VYKAT XR’s safety and prospects, downplaying known red flags (www.rgrdlaw.com). In particular, the complaint charges that Soleno “systematically… concealed significant evidence of safety concerns” – notably severe fluid retention in trial patients – which meant VYKAT XR’s real-world risks (e.g. heart failure, discontinuations, regulatory backlash) were far higher and its commercial viability lower than the rosy picture painted by management (www.rgrdlaw.com). The class action cites the Scorpion report and Soleno’s own admissions in Q3 results as revealing the truth: after August 2025, the short report’s fallout caused a “disruption” in VYKAT XR’s launch trajectory, with fewer new patient starts and rising drop-off rates in the PWS community (www.rgrdlaw.com). On November 4, 2025 – when Soleno announced Q3 earnings and acknowledged these launch issues – the stock collapsed ~27% in one day (www.rgrdlaw.com). Now, multiple investor rights law firms (Robbins Geller, Hagens Berman, Rosen Law, etc.) have opened investigations or filed suits, urging shareholders who suffered losses to act before the lead plaintiff deadline of May 5, 2026 (www.rgrdlaw.com). In summary, Soleno finds itself at a critical juncture: a one-product company riding a high-cost orphan drug launch, but beset by serious safety questions and fraud allegations that threaten its credibility and valuation.

Dividend Policy & Yield (AFFO/FFO)

Soleno has never paid a dividend, and given its profile as a growth-stage biotech, no dividend is expected in the foreseeable future (cdn.yahoofinance.com) (cdn.yahoofinance.com). The company explicitly affirms a zero dividend policy – retained earnings are reinvested into R&D and commercialization rather than distributed to shareholders (cdn.yahoofinance.com). This is reinforced by Soleno’s venture debt covenants, which restrict any dividends or stock buybacks while the loan is in place (cdn.yahoofinance.com). As a result, SLNO’s dividend yield is 0%, and typical real estate metrics like AFFO/FFO do not apply here. Instead, investors gauge Soleno on its product revenue growth and eventual earnings power rather than cash distributions. Notably, Soleno only achieved positive net income in 2025 after VYKAT XR’s launch (roughly $0.40 EPS for 2025 (www.globenewswire.com)), following many years of losses. Going forward, the company’s ability to generate and grow free cash flow will depend entirely on VYKAT XR’s commercial trajectory – a risky proposition given current challenges. In short, SLNO offers no income component for investors; it is purely a high-risk, potential high-reward growth story tied to a single drug.

Leverage, Debt Maturities & Coverage

Despite its challenges, Soleno’s balance sheet is relatively strong in the near term, thanks to a large equity raise and modest debt. In mid-2025, management bolstered liquidity by raising $230 million gross via an underwritten stock offering (www.globenewswire.com) (www.globenewswire.com). This cash infusion swelled Soleno’s cash and investments to $556.1 million as of Q3 2025 (www.globenewswire.com) (and around $600 million by year-end 2025, after additional operating cash inflows (www.globenewswire.com)). Leverage is low – the company carries only a $50 million term loan facility with Oxford Finance, which was drawn after FDA approval (cdn.yahoofinance.com) (cdn.yahoofinance.com). Importantly, this venture debt is long-dated and flexible: it has a 5-year term (interest-only for 48 months), with no principal due until at least February 2029 (cdn.yahoofinance.com). If Soleno hits certain milestones by late 2025/2026, the interest-only period extends to 2029 and final maturity to December 2030 (cdn.yahoofinance.com) (cdn.yahoofinance.com). The loan’s interest rate is 1-month SOFR + 5.50% (floating, currently around low-double-digits) and requires a 5% final fee at maturity (cdn.yahoofinance.com) (cdn.yahoofinance.com). There are no near-term debt maturities or significant mandatory payments – only monthly interest estimated at ~$5 million per year. In effect, Soleno has net cash of roughly $450–500 million (cash far exceeds the $50M debt), giving it a substantial runway for operations and potential legal costs. From a coverage standpoint, Soleno’s recent jump to profitability greatly improves its ability to cover interest obligations. For Q3 2025, interest expense was about $1.4 million (cdn.yahoofinance.com) versus $26 million in net income (www.globenewswire.com) – an ample coverage ratio for that quarter. Even on a cash flow basis, operating cash generation of $48.7 million in Q4 2025 dwarfed the quarterly interest burden (www.globenewswire.com). Moreover, the Oxford loan agreement includes a minimum revenue covenant from mid-2026, but this covenant is waived as long as Soleno’s cash or market cap stay above certain thresholds (cdn.yahoofinance.com). Given the current cash hoard, Soleno appears unlikely to violate covenants in the short term. However, investors should note the potential long-term leverage: the debt facility allows Soleno to borrow up to $200 million (additional tranches of $50M and $25M could be drawn through 2026, plus $25M on milestones) (cdn.yahoofinance.com). Management so far refrained from drawing more in 2025 (cdn.yahoofinance.com), likely because cash was plentiful. But if VYKAT XR falters commercially, Soleno might either tap more debt (raising interest obligations) or burn through its cash cushion. Finally, the debt covenants bar dividends and limit new debt or asset sales (cdn.yahoofinance.com), which aligns with Soleno’s current strategy but could constrain flexibility if the company needed to pivot. Overall, Soleno’s leverage is modest and well-termed, and interest coverage is comfortable at present. The company’s half-billion in cash provides a buffer for adversity – a critical asset as it navigates litigation and a challenged drug launch.

Valuation & Comparables

Soleno’s valuation reflects both the promise and peril of its situation. After the post-earnings selloff in November 2025, Soleno’s market capitalization stood around HK$19.36 billion – roughly US$2.5 billion (companiesmarketcap.com) (companiesmarketcap.com). At that level, investors were paying about 13 times Soleno’s annualized Q4 2025 sales run-rate (annualizing Q4’s $91.7M revenue gives ~$367M) and well over 10 times actual 2025 revenues ($190M) (www.globenewswire.com). On an earnings basis, the stock looks even pricier: with 2025 EPS of $0.39 (www.globenewswire.com), the P/E was north of 100× at the ~$46 share price prevailing after Q3. Clearly, the market had been discounting rapid growth and future profits from VYKAT XR’s rollout. Indeed, in Q4 2025 the drug’s sales surged to $91.7M (up ~39% from Q3’s $66M) (www.globenewswire.com), suggesting an impressive initial uptake. If sustained, this trajectory could make Soleno’s revenue base much larger in 2026 – potentially justifying a high multiple for a rare-disease franchise. However, Soleno’s valuation now faces severe pressure from the safety scare and class action. The stock fell from all-time highs (above $60–$70) in mid-2025 to the mid-$40s by late 2025, and investor sentiment remains fragile. The current market cap still assumes that VYKAT XR will achieve broad adoption and multi-year growth as a cornerstone therapy in PWS. By contrast, short-seller Scorpion Capital argues Soleno is a “one-trick pony” with no pipeline and an “inferior” drug that could implode if safety issues persist, noting Soleno’s core patent expires in 2026 (www.globenewswire.com). (It’s worth noting that VYKAT XR has Orphan Drug exclusivity in the U.S. for 7 years post-approval, i.e. until 2032 (www.sec.gov) (www.sec.gov), which limits generic competition despite the patent timeline). Peer comparisons: There are few direct comps to Soleno, but other orphan drug biotechs with a single commercial product often trade at high price-to-sales multiples early on, reflecting anticipated growth. For example, companies like Rhythm Pharmaceuticals (with an orphan obesity drug) or Avidity Biosciences (pre-commercial) have commanded >10× sales valuations when prospects are strong. That said, those valuations can crumble if uptake disappoints or safety concerns emerge. In Soleno’s case, the overhang of potential FDA action or reputational damage makes its premium valuation tenuous. Investors essentially face a binary scenario: either VYKAT XR overcomes the headwinds and solidifies a monopoly in PWS (supporting significant revenue expansion and perhaps eventual profits to justify a multi-billion valuation), or the safety/regulatory fallout curtails the drug’s use, in which case the stock could have far more downside. It’s notable that insiders have taken some profits – Soleno’s CFO and other executives adopted 10b5-1 trading plans in Q3 2025 to systematically sell shares into strength (cdn.yahoofinance.com) (cdn.yahoofinance.com). Combined with heavy stock-based compensation grants (over $70M in 2024 contributed to the large loss that year (www.globenewswire.com)), this raises some governance questions that may factor into how the market prices the stock. Bottom line: At ~$2–3 billion market cap, Soleno’s valuation is rich relative to current fundamentals, baking in optimism that VYKAT XR’s launch can get back on track. This optimism is counterbalanced by unusual risks, making SLNO’s risk/reward profile extreme even by biotech standards.

Key Risks & Red Flags

Soleno faces an array of risks and red flags, many highlighted by the class action and short-seller allegations:

– Safety Concerns for VYKAT XR: The most immediate risk is the drug’s safety profile. Reports of severe fluid retention leading to hospitalizations (and at least one patient death) have shaken confidence (www.businesswire.com) (www.businesswire.com). If VYKAT XR is indeed causing cardiac failure or other serious adverse events in PWS patients, regulators could intervene – from adding black-box warnings to suspending the drug. Soleno claimed a “compelling efficacy and safety profile” in its trials (www.globenewswire.com), but the lawsuit alleges these claims concealed known issues (www.rgrdlaw.com). An FDA investigation or post-marketing requirement is possible. Already, the PWS medical community is on alert, as evidenced by higher discontinuation rates after the Scorpion report (www.rgrdlaw.com). Any further safety signal (e.g. additional deaths or serious events reported in 2026) would be a major red flag that could derail commercial adoption or even the drug’s approval status.

– Allegations of Data Misrepresentation: Beyond clinical risks, the integrity of Soleno’s trial data is under scrutiny. Scorpion Capital’s report boldly labeled Soleno’s Phase 3 trials a “sham” – citing red flags for suspect data in an open-label withdrawal study and anecdotes from ex-employees questioning scientific practices (www.businesswire.com). Such claims, if validated, imply potential fraud in the FDA submission. While these are currently allegations, the class action will likely seek internal documents on whether Soleno knew of trial irregularities or downplayed adverse data. This is a serious overhang: if discoveries in the lawsuit show any deliberate concealment of safety data (e.g. management emails about unreported edema cases), it could not only bolster the investor suit but also invite SEC enforcement or DOJ investigation for securities fraud. In short, credibility risk is high – management’s statements are suspect until this cloud clears.

– Single-Product Dependency: Soleno has no other approved products or significant pipeline to diversify risk (www.globenewswire.com). VYKAT XR (DCCR) accounted for 100% of 2025 revenues. This one-trick model inherently amplifies every risk – safety, regulatory, commercial – because the company’s fate hinges entirely on one asset. If VYKAT XR falters, Soleno has little else to fall back on (aside from ~$500M cash which would burn quickly if the drug is pulled or sales plummet). The company may eventually use its cash to in-license or acquire new candidates, but any such strategy will take time and could dilute focus. For now, investors are effectively “all-in” on VYKAT XR.

– Reliance on Key Prescribers / Market Concentration: According to Scorpion, Soleno’s early sales were unusually reliant on a single physician in Gainesville, Florida – the lead investigator in trials – who generated a large portion of initial patient prescriptions (www.globenewswire.com). This raises the red flag of concentrated demand: if one champion doctor (possibly an outlier) was fueling the start forms, sustainable broad uptake may be much lower. It also hints at a potential conflict of interest, if that physician has ties to Soleno or was predisposed to use VYKAT XR widely. Should this doctor pull back (or face scrutiny), new patient starts could drop sharply. More generally, trust within the PWS specialist community is critical – and the short report’s implication that some early usage was “artificially” boosted by an enthusiastic insider could dent credibility with other endocrinologists/geneticists treating PWS.

– Patent Expiration and Intellectual Property: While Soleno enjoys 7-year orphan exclusivity in the U.S., the underlying compound (diazoxide) is a decades-old generic, and Soleno’s primary patent expires in 2026 (www.globenewswire.com). This means competitors could attempt to introduce their own extended-release diazoxide after 2026, especially if VYKAT XR remains lucrative and the only game in town. Orphan Drug exclusivity should prevent exact same indication competition until 2032 (www.sec.gov) (www.sec.gov), but there are scenarios where rivals attempt slightly different indications or formulations. Moreover, if Soleno’s trial data integrity is questioned, competitors might challenge Soleno’s IP or FDA approval via Orange Book patent challenges or even petitions. The class action notes the risk that Soleno’s “core patent” running out exposes the company to long-term competitive or generic threats (www.globenewswire.com) – essentially a warning that Soleno’s high pricing ($500K/year per patient) may invite scrutiny and alternatives down the line. Given that VYKAT XR is basically a reformulation of a 50-year-old drug (www.rgrdlaw.com), payers or physicians might eventually seek cheaper options (e.g. compounding the generic diazoxide differently), especially if safety issues reduce the perceived value.

– Financial Reporting and Stock Compensation: An area of potential concern in Soleno’s financials is the lavish stock-based compensation associated with the approval milestone. In 2024, the company’s net loss ballooned to $175.9M (www.globenewswire.com) largely due to $70M+ in stock comp expense as performance awards vested on NDA acceptance. In Q4 2025, stock comp was much lower, contributing to positive earnings, but such swings highlight aggressive executive incentives. While rewarding the team for drug approval is understandable, the optics of huge stock grants (and insiders setting up pre-arranged sales in 2025 (cdn.yahoofinance.com)) could be viewed as a governance red flag – especially if those insiders were aware of undisclosed problems while selling. Any hint of insider enrichment at the expense of shareholders will not play well in court or with institutional investors.

– Legal and Regulatory Overhang: The securities class action itself is a significant risk. Litigation can be costly (even if insured) and distracting for management. If the case proceeds, discovery may unearth damaging information. In the best case, Soleno might settle (perhaps for tens of millions) without admitting wrongdoing. In the worst case, the suit could invite regulators to investigate (SEC or even criminal authorities if egregious fraud is found). Additionally, patient advocacy groups or families could consider legal action if they believe they were misled about the drug’s risks. The headline risk from ongoing press releases by law firms (“SLNO Investors: Act Now!”) (hk.marketscreener.com) (www.globenewswire.com) can also weigh on the stock and harm Soleno’s reputation with its core customer base (physicians and patients). Until these issues are resolved, investors face uncertainty on multiple fronts.

In sum, Soleno’s risk profile is exceptionally high. The company is juggling a delicate situation: it must restore confidence in VYKAT XR’s safety to keep the PWS community and regulators on board, all while defending against allegations that it wasn’t truthful with investors. The red flags – from drug safety and trial integrity to one-product dependence and insider actions – mean that executing a successful launch will be far more challenging than it appeared at approval time. Any further misstep could compound the damage, whereas overcoming these issues could eventually vindicate the company (and potentially punish the shorts). For now, caution is warranted.

Open Questions & Outlook

Looking ahead, several critical questions remain open about Soleno’s future:

– Can Soleno Rebuild Trust in VYKAT XR? Restoring physician and patient confidence is paramount. Will Soleno provide transparent updates on post-marketing safety data? For instance, how many cases of severe edema or cardiac events have occurred, and how is the company mitigating these (e.g. improved monitoring or dosage adjustments)? It’s notable that on the Q3 2025 call, management acknowledged a “disruption” from the short-seller’s report (www.rgrdlaw.com). The open question is whether this disruption is temporary or a lasting cloud. Investor sentiment likely hinges on the next few quarters’ prescription trends – a stabilization or renewed growth in patient starts would signal that the initial scare is being overcome, whereas continued stagnation or high discontinuation rates would confirm a deeper issue.

– What Will the FDA and Other Regulators Do? Thus far, VYKAT XR remains on the market. But the FDA could be quietly reviewing safety reports. Will the FDA demand a label change or additional warnings? Could they require a post-approval study to further assess long-term safety in PWS patients? Another angle: European approval. Soleno had Orphan Drug designation in the EU (www.sec.gov) – will it file for EMA approval, or has the U.S. fallout delayed international plans? A decision to seek approval abroad (or not) in 2026 will be telling: pressing forward might mean confidence in the drug’s profile, while hesitation could imply unresolved safety questions.

– How Will the Class Action Unfold? The legal process will likely stretch over 2026–2027. A near-term question is who will be appointed lead plaintiff (the Robbins Geller suit lists an institutional investor, hinting that a sizable shareholder is driving the case (www.rgrdlaw.com)). If more evidence comes out (via court filings or investigative journalism), it could sway public opinion. For example, if internal emails or trial records show knowledge of hospitalizations that weren’t disclosed, it would severely damage Soleno’s defense. Alternatively, Soleno might try to get the case dismissed or settle early. Any resolution (or lack thereof) by the May 2026 lead plaintiff deadline and beyond will influence the stock – a dismissal would remove a cloud, whereas a class certification and vigorous litigation would prolong uncertainty. Investors should watch for updates on this case from credible sources or court dockets.

– Will Management Changes Occur? Often in situations like this, companies consider leadership changes or additions to signal a fresh start. Soleno’s CEO (Dr. Anish Bhatnagar) has been publicly very bullish on VYKAT XR (www.globenewswire.com). If trust erodes further, the board might face pressure to bring in new expertise (for example, a Chief Medical Officer with a stellar safety track record, or a new board member representing shareholders). It’s an open question whether Soleno’s board is taking the allegations seriously enough to implement governance changes. Any such moves (or lack thereof) will be closely scrutinized.

– Commercial Trajectory and Adjustments: On the business front, how will Soleno adapt its commercial strategy given the controversy? Thus far, uptake was strong (over 1,000 patient start forms by Q3 2025 (www.globenewswire.com), and net revenue reached $190M in ~9 months of sales). But if growth slows, Soleno might need to re-evaluate pricing or patient support. For instance, will the company consider a risk management program or expanded patient monitoring to reassure prescribers? Could it adjust the price or offer refunds in case of severe side effects to maintain goodwill? The answers will determine if VYKAT XR can become a sustainable, long-term therapy or if its use will be limited to a narrower subset of patients.

– Cash Deployment and Pipeline: With approximately $500M in cash, Soleno’s next steps with that capital are in question. Does management hunker down and use the war chest to support VYKAT XR’s launch and legal expenses exclusively? Or will they pursue diversification – such as acquiring or licensing another rare disease asset to reduce one-drug risk? Investors may prefer Soleno to prove VYKAT XR’s success before branching out. However, if confidence in VYKAT XR dims, deploying cash to find a second act might become a strategic imperative. Any hints of deal-making or R&D pipeline expansion in 2026 will be telling. The class action and stock drop also make Soleno itself a potential target – conceivably, a larger pharma with orphan drug experience might see value in VYKAT XR (especially if they think the safety issue is manageable) and consider an acquisition while the stock is depressed. While purely speculative, this scenario cannot be ruled out and is surely on investors’ minds.

– Long-Term Market Potential: Finally, the overarching question: What is the realistic peak opportunity for VYKAT XR? Before controversy, bulls believed VYKAT XR could become standard of care for thousands of PWS patients (with some seeing global sales well above $500M/year given the high price). Now, there is uncertainty – perhaps only the most severe cases or those with close monitoring will use it, capping adoption. If Soleno can demonstrate that adverse events are rare and manageable, the narrative could shift back to growth. If not, one could see physicians holding off prescribing, awaiting more data or alternative treatments. There are competing therapies in development (albeit none approved yet for PWS hyperphagia) – for example, hormone analogs and appetite regulators that failed before might re-enter trials. Soleno’s first-mover advantage could evaporate if it stumbles. Thus, understanding the true benefit-risk profile of VYKAT XR in the coming year will answer whether this drug is a breakthrough or a cautionary tale.

In conclusion, Soleno Therapeutics is at a crossroads. The next 6–12 months will likely answer these open questions and determine whether SLNO was an overhyped story or a genuine medical advancement temporarily waylaid by controversy. Investors are on high alert, as indicated by the “SLNO ALERT” headlines and class action calls to action. Until clarity emerges, this stock will trade more on news flow and trust than on traditional fundamentals. Caution and rigorous due diligence are advised – both for investors considering the stock and for the company’s leadership, who must act decisively to address the myriad risks facing Soleno.

Sources: Soleno Therapeutics SEC filings and press releases; Robbins Geller class action summary (www.rgrdlaw.com) (www.rgrdlaw.com); Hagens Berman and Business Wire reports on Scorpion Capital’s allegations (www.globenewswire.com) (www.businesswire.com); Soleno Q3 & Q4 2025 financial results (www.globenewswire.com) (www.globenewswire.com); CompaniesMarketCap data on valuation (companiesmarketcap.com); and other cited references throughout.

For informational purposes only; not investment advice.